Preliminary results of this study, based on the planned interim analysis after 74 events, were presented as oral presentation during 12 ICML in Lugano on 20th June 2013 and during the Polish Lymphoma Research Group meeting on 7th November 2017 in Warsaw.

**Key description:** In this prospective, multicentre, phase III randomized study by the Polish Lymphoma Research Group, the efficacy and toxicity of R‐CHOP regimen with rituximab maintenance (RM) were compared with standard R‐CVP regimen with RM in untreated patients with indolent lymphoma. After the median follow‐up of 70 months, no significant differences in EFS, PFS and OS were observed with higher toxicity of R‐CHOP.

Rituximab (R)‐based immunochemotherapy is a standard initial treatment of patients with advanced indolent non‐Hodgkin lymphomas (iNHLs) (Casulo *et al.*, [2017](#bjh16264-bib-0002){ref-type="ref"}). Adding R to either CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or CVP (cyclophosphamide, vincristine, prednisone) regimens in randomized controlled trials (RCTs) improved event‐free (EFS), progression‐free (PFS), and overall survival (OS) (Hiddemann *et al.*, [2005](#bjh16264-bib-0007){ref-type="ref"}; Marcus *et al.*, [2005](#bjh16264-bib-0011){ref-type="ref"}; Marcus *et al.*, [2008](#bjh16264-bib-0012){ref-type="ref"}; Bachy *et al.*, [2013](#bjh16264-bib-0001){ref-type="ref"}). The PRIMA study demonstrated a significant PFS benefit to two‐year rituximab maintenance (RM) *versus* no maintenance in patients with follicular lymphoma (FL) responding to R plus alkylator‐based chemotherapy (Salles *et al.*, [2010](#bjh16264-bib-0016){ref-type="ref"}), and RM is generally accepted as the standard of care (Nastoupil *et al.*, [2014](#bjh16264-bib-0014){ref-type="ref"}; Madsen *et al.*, [2018](#bjh16264-bib-0010){ref-type="ref"}). Several RCTs were designed to identify an optimum induction therapy for iNHLs or FL. In the StiL study, bendamustine plus R (BR) demonstrated improved PFS and less toxicity as compared to R‐CHOP (Rummel *et al.*, [2013](#bjh16264-bib-0015){ref-type="ref"}). In the BRIGHT study, BR was non‐inferior to R‐CHOP or R‐CVP in terms of complete remission rate (CRR) in first‐line therapy with a safety profile distinct from standard regimens; however, direct comparison of BR to R‐CVP or R‐CHOP was not possible (Flinn *et al.*, [2019](#bjh16264-bib-0006){ref-type="ref"}). The FOLL05 trial compared R‐CVP *versus* R‐CHOP *versus* R‐FM (rituximab, fludarabine, mitoxantrone) for the initial treatment of patients with advanced symptomatic FL and improved PFS and time to failure (TTF) with R‐CHOP or R‐FM over R‐CVP with no OS difference, and R‐CVP was shown to have the lowest toxicity (Federico *et al.*, [2013](#bjh16264-bib-0005){ref-type="ref"}; Luminari *et al.*, [2018](#bjh16264-bib-0009){ref-type="ref"}). None of the prior studies directly compared R‐CHOP with R‐CVP induction regimens followed by RM. Therefore, the choice of induction chemotherapy is still debatable (Casulo *et al.*, [2017](#bjh16264-bib-0002){ref-type="ref"}).

We report here on the results of a prospective randomized trial directly comparing two induction immunochemotherapy regimens: R‐CVP and R‐CHOP with RM in both arms in patients with iNHLs. The PLRG4 study is registered with ClinicalTrials.gov (identifier: NCT00801281).

Patients and methods {#bjh16264-sec-0002}
====================

Patient selection {#bjh16264-sec-0003}
-----------------

Eligible patients were ≥18 years old with histologically confirmed FL grade 1, 2, 3a, marginal zone lymphoma (MZL), including mucosa‐associated lymphoid tissue (MALT) type, small lymphocytic lymphoma (SLL) (with bone marrow involvement \<30%), and lymphoplasmacytic lymphoma/Waldenström Macroglobulinaemia (LPL/WM). Other main inclusion criteria included Ann Arbor stage II--IV; at least one measurable lesion; previously untreated, with indications for therapy including presence of B symptoms, complications or symptoms related to lymphoma, cytopenia related to bone marrow or spleen involvement, progression of lymphoma within the last 2 months; Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status (PS) ≤2. Patients with grade 3b FL, transformed lymphoma and CNS involvement were excluded from the study. The full list of inclusion/exclusion criteria is presented in Table SI in the Appendix. Written informed consent was obtained for each patient. The study was approved by the independent central Ethics Committee at the Maria Sklodowska‐Curie Institute--Oncology Centre and conducted according to the principles of the Declaration of Helsinki 1964 (with further amendments) and Good Clinical Practice guidelines.

Randomization {#bjh16264-sec-0004}
-------------

Eligible patients were centrally randomized (1:1) with the use of a web response system to standard arm R‐CVP or experimental R‐CHOP. Randomization was stratified by centre and lymphoma subtype. A minimization technique was used to balance treatment over strata.

Study design {#bjh16264-sec-0005}
------------

PLRG4 was a phase III, open‐label, randomized study, recruiting patients in 14 sites in Poland. Patients in the R‐CVP arm received R 375 mg/m^2^ iv on day 1, cyclophosphamide (CP) 750 mg/m^2^ iv on day 1, vincristine (VCR) 1·4 mg/m^2^ (max. 2 mg) iv on day 1, prednisone 40 mg/m^2^ orally on days 1--5 every 21 days (Q21D); and patients in the R‐CHOP arm received the same drugs plus doxorubicin 50 mg/m^2^ iv on day 1, with prednisone 100 mg orally on days 1--5 Q21D, until complete remission plus two cycles for a maximum of eight cycles. Restaging was performed after cycle 4 and after completion of induction therapy. Two months after the last induction chemotherapy, RM was initiated in responding patients (CR/PR) with R 375 mg/m^2^ IV every 2 months (Q2M) for 12 cycles or 24 months. Follow‐up visits were scheduled Q3M until an event or up to three years after therapy.

The primary endpoint was event‐free survival (EFS), defined as time from randomization to disease progression (PD), relapse, change of lymphoma therapy, serious adverse event (SAEs) resulting in patient withdrawal, patient refusal, or death from any cause. Secondary endpoints included: response rate (RR), time to best response (TBR), PFS, duration of response (RD), overall survival (OS), rate of febrile neutropenia, rate of infection (Table SII). Response was evaluated according to revised International Workshop Criteria (Cheson *et al.*, [1999](#bjh16264-bib-0003){ref-type="ref"}; Cheson *et al.*, [2007](#bjh16264-bib-0004){ref-type="ref"}). Response to treatment was evaluated with CT scans after four cycles, after end of induction (after six or eight cycles), and within 4 weeks of completion of maintenance. PET/CT was not required and was performed occasionally at the discretion of investigators. Data on adverse events (AEs) and SAEs were obtained for up to 110 days after last dose of study treatment. AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (<https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf>; accessed 13 June 2018).

Histological diagnosis was done locally including 40% of patients diagnosed at two sites hosting the national hematopathology reference centres. Primary diagnostic samples were centrally reviewed (20% of patients) at the discretion of the treating physician. Response to treatment was evaluated with CT scans after four cycles, after end of induction (after six or eight cycles), and within 4 weeks of completion of maintenance. PET/CT was not required and was performed occasionally at the discretion of investigators.

Statistical analysis {#bjh16264-sec-0006}
--------------------

We assumed a median EFS difference of 18 months as clinically meaningful in favour of the experimental arm R‐CHOP with 147 events needed to provide 80% power for the two‐sided log rank test to detect an expected difference at a 0·05 level of significance. Assuming a 10% drop‐out rate, a total number of 250 patients had to be recruited over 3 years and 4 months (125 per arm) and followed for 3 years and 6 months. Interim analyses were planned after 37, 74 and 111 events according to O\'Brian and Fleming with levels of significance of 0·00009, 0·0055 and 0·022 respectively. The final analysis was performed after a median of 67 months of follow‐up with a 0·04 level of significance. Safety analysis was performed yearly. The Kaplan--Meier method was used to calculate survival curves and the two‐sided log rank test was used for comparing time‐to‐event distributions. The Cox model was applied for estimating appropriate hazard ratios. The chi‐square test or exact Fisher test was used to compare percentages. To compare the distributions of continuous variables, a two‐sided *t*‐test or the Mann--Whitney nonparametric test was used. All statistical analyses were performed using IBM SPSS Statistics version 23.0 (IBM Corp., Armonk, NY).

Results {#bjh16264-sec-0007}
=======

Baseline characteristics {#bjh16264-sec-0008}
------------------------

Between February 2007 and June 2011, 250 eligible patients were randomized to the R‐CVP arm (*n* = 123) and the R‐CHOP arm (*n* = 127) (Fig [1](#bjh16264-fig-0001){ref-type="fig"}). Eleven patients did not start study treatment or discontinued it early due to change of diagnosis after pathology review (*n* = 7), spontaneous disease regression (*n* = 1), absence of active disease documented on PET/CT examination (*n* = 1), and consent withdrawal before study treatment was initiated (*n* = 2). Consequently, 239 patients were included in the final analysis (R‐CVP, *n* = 118; R‐CHOP, *n* = 121).

![Treatment allocation and patients included in the analysis. \[Colour figure can be viewed at wileyonlinelibrary.com\].](BJH-188-898-g001){#bjh16264-fig-0001}

Baseline characteristics of patients were well balanced in the two study arms except for Ann Arbor clinical stage 3--4, which was slightly more prevalent in R‐CHOP arm than in the R‐CVP arm (94·2% vs. 84·7%, *P* = 0·02) Selected variables are presented in Table [1](#bjh16264-tbl-0001){ref-type="table"}, and a full list in Table SIII.

###### 

Selected demographic and clinical features of the patients (*N* = 250).

                        R‐CVP           P‐CHOP          *P*‐value
  --------------------- --------------- --------------- ----------------------------------------------------
  Patients randomized   123             127             
  Patients evaluable    118             121             
  Male/female           55/63           52/69           
  Age, mean (range)     55.9 (25--89)   55.8 (21--80)   
  ≥60                   44 (37.3%)      47 (38.8%)      
  Histology                                             
  FL                    48 (40.6%)      51 (42.2%)      \>0.998[\*](#bjh16264-note-0200){ref-type="fn"}
  MZL/MALT              46 (39%)        46 (38%)        
  SLL                   11 (9%)         11 (9%)         
  LPL/WM                13 (11%)        13 (11%)        
  Ann Arbor stage                                       
  1                     1 (0.8%)        2 (1.7%)        **0.042** [\*](#bjh16264-note-0200){ref-type="fn"}
  2                     17 (14.4%)      5 (4.1%)        
  3                     24 (20.3%)      23 (19.0%)      
  4                     76 (64.4%)      91 (75.2%)      

FL, follicular lymphoma; MZL, marginal zone lymphoma; MALT, mucosa associated lymphoid tissue lymphoma; SLL, small lymphocytic lymphoma; LPL, lymphoplasmacytic lymphoma; WM, Waldenström macroglobulinemia.

*t*‐student test.

John Wiley & Sons, Ltd

Efficacy {#bjh16264-sec-0009}
--------

The EFS was better than expected in both arms and a median was not reached. Consequently, estimation of the difference in median EFS was not possible. After medians at follow‐up (95% CI) of 67 (66, 68), 66 (65, 67) and 70 (68, 71) months respectively, no statistically significant difference was found between study arms regarding EFS, PFS and OS (*P* = 0·386, 0·849 and 0·434 respectively). The corresponding hazard ratios \[HR (R‐CHOP)/(R‐CVP)\] with 95% CIs were 0·840 (0·566, 1·247), 0·955 (0·594, 1·536) and 1·328 (0·651, 2·710) respectively.

The five‐year EFS rates for the R‐CHOP and R‐CVP groups were 0·61 (95% CI; 0·52, 0·70) and 0·56 (95% CI; 0·47, 0·65), five‐year PFS rate was 0·71 (95% CI; 0·62, 0·79) and 0·69 (95% CI; 0·60, 0·78), and five‐year OS was 0·84 (95% CI; 0·78, 0·92) and 0·89 (95% CI; 0·83, 0·95) respectively. EFS curves are presented in Fig [2](#bjh16264-fig-0002){ref-type="fig"}A, and three‐, four‐, five‐year PFS and OS are presented in Fig [3](#bjh16264-fig-0003){ref-type="fig"} and Figure [S1](#bjh16264-sup-0001){ref-type="supplementary-material"}.

![Primary endpoint Event Free Survival in total study population (*P* = 0.386) (A) and by histology subtype (*P* \< 0.001) (B). \[Colour figure can be viewed at wileyonlinelibrary.com\].](BJH-188-898-g002){#bjh16264-fig-0002}

![Progression Free Survival (*P* = 0.849).](BJH-188-898-g003){#bjh16264-fig-0003}

Among 99 FL patients, early progression of disease (POD), i.e. progression within 2 years of the start of treatment, occurred in 8/48 (16·7%) patients in the R‐CVP arm and in 7/51 (13·7%) patients in the R‐CHOP arm; the difference in frequency of early POD between arms was not significant (*P* = 0·68). Early POD was highly significantly associated with reduced OS (HR 23·8, *P* \< 0·001) (Figure [S2](#bjh16264-sup-0002){ref-type="supplementary-material"}A--C).

In post hoc evaluation of EFS by histology subtype (Fig [2](#bjh16264-fig-0002){ref-type="fig"}B), the outcome in SLL patients was significantly (*P* \< 0·001) worse than in patients with other subtypes (FL, MZL, LPL). The same was observed for PFS and OS, with corresponding *P*‐values of \<0·001 and 0·039 (Figures [S3](#bjh16264-sup-0005){ref-type="supplementary-material"} and [S4](#bjh16264-sup-0006){ref-type="supplementary-material"}). The forest plot of hazard ratios for EFS of patients with different histological subtypes by treatment arm is shown in Figure [S5](#bjh16264-sup-0007){ref-type="supplementary-material"}.

The FLIPI high‐risk group had a significant adverse effect on EFS (*P* = 0·015) and OS (0·001) and PFS (*P* = 0·039) of FL patients and IPI risk level had a significant influence on EFS (*P* \< 0·001), PFS (*P* = 0·011), and OS (*P* \< 0·001) of all patients. Corresponding Kaplan--Meier curves for EFS, PFS and OS according to FLIPI and IPI risk are shown in Figures [\[Link\]](#bjh16264-sup-0008){ref-type="supplementary-material"}, [\[Link\]](#bjh16264-sup-0009){ref-type="supplementary-material"}, [\[Link\]](#bjh16264-sup-0010){ref-type="supplementary-material"}, [\[Link\]](#bjh16264-sup-0011){ref-type="supplementary-material"}, [\[Link\]](#bjh16264-sup-0012){ref-type="supplementary-material"}, [\[Link\]](#bjh16264-sup-0013){ref-type="supplementary-material"}.

Overall response rate (CR + PR) in the R‐CVP and R‐CHOP arms was 97·1% and 94·5% respectively (CR = 36·3% and 43·6% respectively) in 212 evaluable patients (Table SIV). There was no difference in response rate (*P* = 0·218) including best response rate (*P* = 0·786) between treatment arms (Table SV). The Kaplan--Meier curves of the best response duration (BRD) in treatment arms are shown in Figure [S11](#bjh16264-sup-0013){ref-type="supplementary-material"}.

Safety {#bjh16264-sec-0010}
------

The number of AEs was higher in the R‐CHOP than in the R‐CVP arm. In total, there were 474 grade 1--4 AEs reported throughout the induction and maintenance period plus 110 days (296 in R‐CHOP and 178 in R‐CVP). The most frequent AE of any grade in the R‐CVP arm was neutropenia (*n* = 18, 10·3%), sensory neuropathy (*n* = 13, 7·4%), and elevated transaminase levels (*n* = 12, 6·9%), while in the R‐CHOP arm most frequent AEs were neutropenia (*n* = 43, 17·0%), leukopenia (*n* = 27, 10·0%) and elevated transaminase levels (*n* = 20, 7·4%). Grade 3--4 AEs were recorded in 65 vs. 22 patients in the R‐CHOP and R‐CVP arm respectively, including neutropenia (*n* = 16 \[11·6%\] vs. *n* = 4 3·4%\]) and infections (*n* = 14 \[10·7%\] vs. *n* = 3 \[2·5%\]). Table SVI in presents asummary of all AEs.

There were four deaths attributed to cardiac arrest (*n* = 2) or heart failure (*n* = 2), one in each arm, and four cardiac events, all in the R‐CHOP arm including grade 1 arrhythmia, grade 1 atrial fibrillation, grade 2 cardiomyopathy and grade 3 circulatory insufficiency.

In total, 10 cases (3 vs. 7, in the R‐CHOP and R‐CVP group respectively) of second malignancies were recorded (lung cancer two, colorectal cancer two, and thyroid, urinary bladder, tongue, nose, uterine and prostate cancer). The Cumulative Incidence Function (CIF) with 95% CI for a second cancer was 1·69% (0·04%, 3·34%) after 1 year, and 4·52% (1·77%, 7·28%) after 6 years. Median time to onset of the second tumour was 12·33 months. Detailed information is presented in Figure [S12](#bjh16264-sup-0014){ref-type="supplementary-material"}.

There were four cases of uncomplicated pregnancy reported: one in the R‐CHOP and three cases in the R‐CVP arm, all in the follow‐up period.

Discussion {#bjh16264-sec-0011}
==========

At the time when this study was designed in 2006, we hypothesized a better outcome of patients treated with R‐CHOP than R‐CVP based on the results of the German Low‐Grade Lymphoma Study Group (GLSG) published soon after the international study of R‐CVP *versus* CVP (Hiddemann *et al.*, [2005](#bjh16264-bib-0007){ref-type="ref"}; Marcus *et al.*, [2005](#bjh16264-bib-0011){ref-type="ref"}). However, with a median follow‐up of more than 5 years, medians of EFS, PFS, or OS in either arm were not reached, and the rates of survival including EFS, PFS, and OS at 5 years were comparable in the R‐CVP and R‐CHOP arms.

Event‐free survival was selected as a primary endpoint in our study based on the consideration of events dependent on therapy tolerance in addition to disease progression or death. EFS and similar endpoints like TTF (time to failure), FFS (failure‐free survival), and recently mPFS (modified PFS) are frequently used in studies where OS is unpractical due to the long natural course of disease or existence of effective salvage treatments (Marcus *et al.*, [2005](#bjh16264-bib-0011){ref-type="ref"}; Marcus *et al.*, [2008](#bjh16264-bib-0012){ref-type="ref"}; Bachy *et al.*, [2013](#bjh16264-bib-0001){ref-type="ref"}). In the pivotal M39021 study comparing R‐CVP with CVP, the median EFS (TTF) for the R‐CVP arm was 27 month at 30 month median follow‐up (Marcus *et al.*, [2005](#bjh16264-bib-0011){ref-type="ref"}; Marcus *et al.*, [2008](#bjh16264-bib-0012){ref-type="ref"}). Based on this outcome, we assumed a reference median EFS of 30 months in the standard arm R‐CVP and expected an improvement by 18 months in the experimental arm R‐CHOP.

However, the patient outcome in our study was better than in the Marcus study (Marcus *et al.*, [2005](#bjh16264-bib-0011){ref-type="ref"}; Marcus *et al.*, [2008](#bjh16264-bib-0012){ref-type="ref"}); median EFS was not reached in either arm, and 48‐month OS for R‐CHOP *versus* R‐CVP was 87% vs. 89% compared to 83% in the R‐CVP arm of the Marcus study. The difference between EFS/TTF in the Marcus and our study as well as the less than expected number of events were most likely due to the use of RM as the current standard of care. Indeed, in the PRIMA study (Salles *et al.*, [2010](#bjh16264-bib-0016){ref-type="ref"}) of FL patients with high tumour burden, two‐year RM reduced the risk of progression and improved EFS compared to no RM with HR 0·55 (95% CI 0·44, 0·68) and 0·59 (95% CI 0·48, 0·72) respectively, and the PFS difference reached 17·3% at 36 months with no difference in OS.

Early POD, a recently discovered powerful risk factor for OS in FL, was associated with markedly reduced OS of FL patients in both arms of our study but there was no statistically significant difference in the frequency of early POD between the treatment arms (Figure [S2](#bjh16264-sup-0002){ref-type="supplementary-material"}A--C).

In contrast to our study, the FOLL05 study (Federico *et al.*, [2013](#bjh16264-bib-0005){ref-type="ref"}) in patients with advanced‐stage FL comparing R‐CVP with R‐CHOP and R‐FM induction regimens, notably without RM, showed a statistically significant difference in three‐year TTF in favour of R‐CHOP (62%) compared to R‐CVP (46%) (*P* = 0·003) as well as a significant three‐year PFS difference of 68% vs. 52% (*P* = 0·011) respectively. However, the FOLL05 study expanded prespecified accrual from 252 to 531 patients due to faster than expected patient enrolment. A subsequent report of this study (Luminari *et al.*, [2018](#bjh16264-bib-0009){ref-type="ref"}) with the follow‐up extended to 7 years confirmed the superiority of R‐CHOP and R‐FM over R‐CVP with an eight‐year TTF of 45% and 49% *vs.* 38% respectively. Again, corresponding figures were higher for our study with five‐year EFS and PFS for R‐CHOP *versus* R‐CVP of 61% vs. 56% and 71% vs. 69% respectively.

An international phase III superiority trial (RELEVANCE) in patients with advanced untreated FL compared a chemo‐free combination of lenalidomide and rituximab with a standard rituximab plus chemotherapy followed by RM in both arms (Morschhauser *et al.*, [2018](#bjh16264-bib-0013){ref-type="ref"}). Chemotherapy included R‐CHOP (72%), R‐B (23%), and R‐CVP (5% of patients). Three‐year PFS in the lenalidomide and chemotherapy arm was 77% and 78% respectively, with a substantial rate of grade 3--4 neutropenia of 32% vs. 50% respectively. The expected 23% superiority in PFS of lenalidomide over the chemotherapy‐containing regimen was not observed. The three‐year PFS of 76% in both arms of our study is almost identical to PFS in the RELEVANCE trial, reflecting the current efficacy of induction immunochemotherapy regimens with the subsequent RM (Madsen *et al.*, [2018](#bjh16264-bib-0010){ref-type="ref"}). Interestingly, in the GALLIUM study (Hiddemann *et al.*, [2018](#bjh16264-bib-0008){ref-type="ref"}), where patient allocation to chemotherapy was not randomized but was stratified, three‐year PFS of patients who received R‐CHOP or R‐CVP assessed by the independent review committee was comparable and similar to the corresponding value in our study: 77% in both groups, and 76% in our study.

In the BRIGHT study, which was recently updated with around five‐year follow‐up, similarly to our study, the medians were not reached for any of the time‐to‐event endpoints for either treatment arm, and five‐year PFS for patients treated with BR and R‐CHOP or R‐CVP was 65·5% and 55·8% respectively. These figures were apparently lower than the corresponding five‐year PFS values in our study (71% and 69% respectively), which possibly resulted from less than half of the patients receiving rituximab maintenance (BR, 43%; R‐CHOP/R‐CVP, 45%) and a component of the mantle‐cell lymphoma (MCL) patients in the BRIGHT study. Even the five‐year PFS in the BR arm (65·5%), which was declared by the authors as a preferred first‐line treatment option for patients with indolent and MCL, was lower than the five‐year PFS of patients in our study treated with R‐CVP (69%), which makes the recommendation debatable.

In addition to FL patients (42%), our study included patients with other iNHL subtypes: MZL/MALT (38%), LPL/WM (11%), and SLL (9%), and randomization was stratified by histology given that principles of therapy were similar for FL and iNHL in 2006, and other studies like StiL (Rummel *et al.*, [2013](#bjh16264-bib-0015){ref-type="ref"}) or BRIGHT (Flinn *et al.*, [2019](#bjh16264-bib-0006){ref-type="ref"}) were addressing this patient population as well. Of note, even though the study was not powered to analyse outcome in histological subsets, it was significantly worse in the SLL subset, which strongly suggests that neither of the treatment arms is appropriate for this group of patients (Fig [2](#bjh16264-fig-0002){ref-type="fig"}B, *P* \< 0·001; Figures [\[Link\]](#bjh16264-sup-0005){ref-type="supplementary-material"}, [\[Link\]](#bjh16264-sup-0006){ref-type="supplementary-material"}, [\[Link\]](#bjh16264-sup-0007){ref-type="supplementary-material"}).

Response rates to induction immunochemotherapy were comparable between treatment arms and the median time to best response was 4 months in both arms. However, the magnitude of complete response rates, i.e. ORR/CR 97·1/36·3% and 94·5/43·6% in the R‐CVP and R‐CHOP arm respectively, was lower than in similar studies. In the FOLL05 study, ORR/CR rates in the R‐CVP and R‐CHOP arms were 88%/67% and 93%/73% respectively (Federico *et al.*, [2013](#bjh16264-bib-0005){ref-type="ref"}) and in the RELEVANCE study, ORR/CR (confirmed/ unconfirmed) rates for the R‐lenalidomide and R‐chemotherapy arms were 61/48% and 65/53% respectively (Morschhauser *et al.*, [2018](#bjh16264-bib-0013){ref-type="ref"}). We used revised response criteria as per Cheson *et al.*([2007](#bjh16264-bib-0004){ref-type="ref"}) where the CRu category was abandoned and counted as PR unless the FDG‐PET scan was negative. However, a PET scan was not obligatory in our study as the primary endpoint was EFS, not response rate, and in fact PET was performed in only seven patients. This may explain why CR rates were lower in our study compared to FOLL05 and RELEVANCE where Cheson *et al.*\'s ([1999](#bjh16264-bib-0003){ref-type="ref"}) criteria were used.

The most frequent AE of any grade in both arms was neutropenia. Other frequent AEs in R‐CVP and R‐CHOP were sensory neuropathy, elevated transaminase levels and leukopenia. Grade 3--4 AEs were recorded in 65 vs. 22 patients in the R‐CHOP and R‐CVP arm respectively, with neutropenia and infections being the most common. We have no data on the use of granulocyte‐colony stimulating factor. Summarizing, AEs were more prevalent with R‐CHOP therapy, which in general is in line with other trials; however, the data comparing toxicity profile of different treatment schemes with rituximab are variable (Hiddemann *et al.*, [2005](#bjh16264-bib-0007){ref-type="ref"}; Federico *et al.*, [2013](#bjh16264-bib-0005){ref-type="ref"}; Rummel *et al.*, [2013](#bjh16264-bib-0015){ref-type="ref"}; Flinn *et al.*, [2019](#bjh16264-bib-0006){ref-type="ref"}). All four cases of pregnancies were reported in the follow‐up period, and pregnancies and deliveries were uncomplicated with healthy newborns.

During the study, we noted 10 cases of second malignancies, with a CIF for second primary malignancy (SM) of 4·52% with 95% CIs of 1·77% and 7·28% after six years and median time to onset of the second malignancy of 12·33 months. This is about half the rate of SM observed in the FOLL05 study of 9·4% at eight years (Luminari *et al.*, [2018](#bjh16264-bib-0009){ref-type="ref"}).

Overall, this multicentre randomized study with \>5 year follow‐up shows a similar outcome for patients with indolent lymphoma in need of systemic therapy treated with R‐CVP or R‐CHOP immunochemotherapy and RM in both arms. The minor toxicity of the R‐CVP regimen makes it a reasonable choice for induction treatment, keeping other active agents like doxorubicin or bendamustin for second‐line therapy.
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**Figure S1.** Overall survival by treatment arm (*P* = 0.434).
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**Figure S2.** (A) Overall survival of 99 FL patients who had (n = 15) or had not (n = 84) early progression of disease (*P* \< 0.001). (B) Overall survival of 48 FL patients in arm R‐CVP who had (n = 8) or had not (n = 40) early progression of disease (*P* \< 0.001). (C) Overall survival of 51 FL patients in arm R‐CHOP who had (n = 7) or had not (n = 44) early progression of disease (*P* \< 0.001).
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**Figure S3.** Progression‐free survival by histology subtype (*P* \< 0.001).
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**Figure S4.** Overall survival by histology subtype (*P* = 0.039).
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**Figure S5.** Forest plot of hazard ratios for event‐free survival of patients with different histological subtypes by treatment arm.
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**Figure S6.** Event‐free survival by FLIPI index, FL group (*P* = 0.015).
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**Figure S8.** Overall survival by FLIPI index, FL group, (*P* = 0.001).
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**Figure S9.** EFS by IPI, whole group, *P* \< 0.001.
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**Figure S10.** PFS by IPI, whole group, *P* = 0.011.

###### 

Click here for additional data file.

###### 

**Figure S11.** OS by IPI, whole group, *P* \< 0.001.
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**Figure S13.** Median time to onset of the second malignancy.
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**Table SI** **.** PLRG‐4 study inclusion and exclusion criteria.

**Table SII** **.** Definition of secondary endpoints.

**Table SIII** **.** Baseline demographic and clinical characteristics of the patients (*N* = 250).

**Table SIV** **.** Response to treatment after induction before maintenance (*P* = 0.218).

**Table SV** **.** Best response distribution (*P* = 0.786).

**Table SVI** **.** Adverse events reported during the study related to treatment group.
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